DiaMedica Therapeutics (DMAC) EBITDA (2018 - 2026)

DiaMedica Therapeutics has reported EBITDA for 9 years, with the latest figure at -$10.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 30.98% year-over-year to -$10.1 million; the trailing twelve-month figure through Mar 2026 stood at -$35.1 million (down 30.33% YoY), and the FY2025 full-year result was -$32.7 million, down 34.03% from the prior year.
• EBITDA for Q1 2026 stood at -$10.1 million, down from -$8.7 million in the prior quarter.
• The five-year high for EBITDA was -$3.1 million in Q3 2022, with the low at -$10.1 million in Q1 2026.
• Historically, EBITDA has averaged -$5.9 million across 5 years, with a median of -$5.2 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA increased 11.53% — and 2024, when it tumbled 58.27%.
• DiaMedica Therapeutics' EBITDA stood at -$3.7 million in 2022, then sank by 37.26% to -$5.0 million in 2023, then plunged by 58.27% to -$8.0 million in 2024, then dropped by 9.83% to -$8.7 million in 2025, then dropped by 15.77% to -$10.1 million in 2026.
• The last three EBITDA figures came in at -$10.1 million (Q1 2026), -$8.7 million (Q4 2025), and -$8.6 million (Q3 2025), per Business Quant data.